Detecting Immunotherapy Side Effects Early With Tissue-Specific cfDNA
In this article
Can immunotherapy side effects be detected before they begin? An early-warning approach using tissue-specific cfDNA in NEJM 2025
Immune checkpoint inhibitors—immunotherapy—have transformed treatment in many cancers. But this power can sometimes cause the immune system to misdirect its attack toward healthy tissues . One of the hardest clinical questions is: How early can we see this wave of side effects coming?
On December 11, 2025, NEJMpublished this brief but striking study investigating whether a blood biomarker—tissue-specific cell-free DNA, or cfDNA)—can reveal multiorgan traces of immune-related adverse events (irAEs). Put simply: Can a signal of organ damage sometimes appear in blood before symptoms and clinical diagnosis?
Note: This content is not medical advice. Individual treatment and monitoring decisions must be discussed with your oncologist.
Where Was This Study Published?
The study appeared in The New England Journal of Medicine (NEJM) as a "To the Editor" correspondence/report. Rather than a large phase 3 trial, it is a brief but informative study that clarifies an idea and demonstrates a method .
Explaining the Study Design in Plain Language
Researchers examined serial blood samples collected over time from patients receiving immunotherapy. Instead of the usual ctDNA question—whether cancer DNA was present—they tried to identify which organs the circulating cfDNA came from .
The rationale is that injury and increased cell death in an organ may raise blood levels of cfDNA carrying that tissue's epigenetic signature. The study compared 6 patients who developed irAEs with 8 patients who did not .
Data Visualization 1: How Much Does the cfDNA "Organ Damage Signal" Increase?
Bar: relative fold increase • Median in the irAE group: 6.1-foldWhy Does This Difference Matter?
Because it suggests the possibility of detecting side effects not only after symptoms and abnormal laboratory results appear, but as the biology of organ damage begins . All patients developing irAEs (6/6) showed organ-specific cfDNA increases, while none without irAEs (0/8) showed a clear increase.
Data Visualization 2: How Early Can an "Early Warning" Come?
In the examples presented, the cfDNA organ damage signal rose in some patients days to months before clinical irAE diagnosis: 4 days, 20 days and even 236 days in advance.
Important nuance: These values are individual examples; they do not mean every patient receives the same advance warning.
What Are cfDNA and "Tissue Specificity"?
cfDNA consists of small DNA fragments circulating in blood. Their epigenetic signatures —such as methylation patterns—can help predict their tissue of origin. Using this approach, the study aims to create an origin map showing whether DNA comes from the liver, heart, intestines, or elsewhere.
Data Visualization 3: The Concept of Multiorgan Signals
This panel illustrates the concept: irAEs may increase signals from several organsNote: This grid conceptually lists organ examples in the article; it does not mean every organ is affected in every patient.
The Critical Patient Question: "Will This Test Be in Clinics Tomorrow?"
Not yet. This is early evidence that the approach is feasible . Routine use requires validation in larger groups, standardization, and a clear decision pathway specifying what to do when thresholds are exceeded.
It is nevertheless a step in the right direction, toward proactive rather than reactive side-effect monitoring.
A Take-Home Message
During immunotherapy, contact your team promptly for new symptoms such as breathlessness, diarrhea, palpitations, jaundice, or rash. This article offers a future possibility: One day, we may receive organ-level early warnings even before symptoms begin.
Source: “Molecular Evidence of Multiorgan Damage Associated with Immune-Related Adverse Events.” N Engl J Med (NEJM), 2025. (Report published in "To the Editor" format).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.